{"id":4842,"date":"2025-05-28T02:17:40","date_gmt":"2025-05-28T05:17:40","guid":{"rendered":"https:\/\/mbinitiative.org\/?page_id=4842"},"modified":"2025-06-25T14:54:05","modified_gmt":"2025-06-25T17:54:05","slug":"impact-report","status":"publish","type":"page","link":"https:\/\/mbinitiative.org\/pt\/impact-report\/","title":{"rendered":"Relat\u00f3rio de Impacto"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Relat\u00f3rios<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tSetembro 2024<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tFevereiro 2025<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tMaio de 2025<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tSetembro 2025<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\n\t\n<\/svg>\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The
\nMedulloblastoma
\nInitiative<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Relat\u00f3rio de Impacto<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Maio de 2025<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Duane Mitchell, MD, PhD,\nlidera o primeiro ensaio\ncl\u00ednico da MBI aprovado\npelo FDA na Universidade\nda Fl\u00f3rida<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Fazendo hist\u00f3ria: nosso primeiro ensaio cl\u00ednico come\u00e7ou<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A Medulloblastoma Initiative (MBI) est\u00e1 ajudando a transformar\no campo da pesquisa sobre tumores cerebrais. Neste ano,\npesquisadores da Universidade da Fl\u00f3rida deram in\u00edcio ao primeiro\nensaio cl\u00ednico da MBI.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201cSonhamos com a chegada deste momento\u201d, <\/strong>diz Fernando Goldsztein,\nfundador da MBI. \u201cNosso primeiro ensaio cl\u00ednico mostra o que podemos\nrealizar juntos. Gra\u00e7as aos apoiadores da MBI, crian\u00e7as com tumores\nincur\u00e1veis finalmente t\u00eam uma nova esperan\u00e7a. Temos o potencial de salvar\nmilhares de vidas, e n\u00e3o vamos parar em um \u00fanico estudo. N\u00e3o temos\ntempo a perder\u201d.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O primeiro ensaio cl\u00ednico foi aprovado pela Food and Drug\nAdministration (FDA), ag\u00eancia reguladora dos Estados Unidos, no ano\npassado. Ele foi batizado pela equipe da Fl\u00f3rida de MATCHPOINT.\nO tratamento inovador combina c\u00e9lulas T do pr\u00f3prio paciente com um medicamento que\najuda o sistema imunol\u00f3gico a derrotar as defesas do tumor, abrindo caminho para avan\u00e7os\nrevolucion\u00e1rios na terapia contra o c\u00e2ncer.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O recrutamento para o estudo come\u00e7ou em mar\u00e7o, na Fl\u00f3rida. O Hospital Children\u2019s National, em\nWashington, D.C., tamb\u00e9m iniciar\u00e1 o recrutamento em breve. Os dois primeiros pacientes foram\ninclu\u00eddos no ensaio em maio. A expectativa \u00e9 admitir 12 pacientes ao longo dos pr\u00f3ximos 2 anos.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Utilize este c\u00f3digo QR\npara saber mais<\/span><\/a> sobre\no recrutamento para o\nestudo MATCHPOINT<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O MATCHPOINT visa eliminar tumores recorrentes, atacando-os de forma precisa por m\u00faltiplos\n\u00e2ngulos. \u201cO RNA nos d\u00e1 um mapa de quais prote\u00ednas s\u00e3o produzidas dentro das c\u00e9lulas tumorais\u201d,<\/strong>\nexplica o Dr. Duane Mitchell, MD, PhD, que conduz o ensaio. \u201cNa \u00faltima d\u00e9cada, minha equipe\ndesenvolveu tecnologias gen\u00e9ticas que utilizam esse mapa para personalizar os tratamentos de\nimunoterapia. O ensaio cl\u00ednico utilizar\u00e1 esses tratamentos em combina\u00e7\u00e3o com medicamentos que\nremovem os mecanismos de autodefesa dos tumores. Isso nos permitir\u00e1 atacar e eliminar as c\u00e9lulas\ntumorais que n\u00e3o podem ser removidas cirurgicamente.\u201d<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201c<\/strong><\/em> O MATCHPOINT mostra o caminho a ser seguido. A MBI n\u00e3o descansar\u00e1 at\u00e9 que tenhamos tratamentos eficazes para o meduloblastoma recidivado. Sou grato \u00e0 nossa comunidade global de apoiadores, que se juntou ao nosso movimento. Juntos, estamos mudando o mundo, fomentando a ci\u00eancia colaborativa com uma meta: encontrar curas.<\/span><\/em><\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2014 Fernando Goldsztein<\/strong>
Fundador da MBI<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201c<\/strong><\/em> Esta \u00e9 uma oportunidade real. \u00c9 fenomenal que o ensaio cl\u00ednico tenha iniciado. Pode ter um retorno real, n\u00e3o apenas para os pacientes do estudo, mas tamb\u00e9m para outros projetos do Cons\u00f3rcio.<\/span><\/em><\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2014 Roger J. Packer, MD<\/strong>
Diretor, Brain Tumor Institute, Hospital Children\u2019s National, Washington, D.C.;
Pesquisador principal, Cons\u00f3rcio Cure Group 4<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O MATCHPOINT \u00e9 um dos dois ensaios cl\u00ednicos aprovados pela FDA na Universidade da Fl\u00f3rida,\nviabilizados pelos investimentos da MBI. O segundo ensaio, com in\u00edcio previsto para o final deste\nano, testar\u00e1 uma vacina de mRNA semelhante \u00e0s desenvolvidas para a covid-19. A abordagem\ninovadora, liderada pelo Dr. Elias Sayour, MD, PhD, tem o potencial de gerar uma resposta\nimunol\u00f3gica robusta em pacientes para prevenir a recorr\u00eancia do tumor<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Nos pr\u00f3ximos meses, com o apoio da MBI, o Dr.\nMitchell planeja lan\u00e7ar um terceiro ensaio, que\nlevar\u00e1 o MATCHPOINT um passo adiante. O Dr.\nMitchell desenvolveu uma nova plataforma de\nintelig\u00eancia artificial que pode potencializar a\nimunoterapia, atingindo tumores com muito mais\nprecis\u00e3o.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Seu apoio alimenta a esperan\u00e7a<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A MBI e o Hospital Children\u2019s National\napresentam este relat\u00f3rio com um\nprofundo agradecimento pelo seu\napoio ou interesse em se juntar ao\nnosso movimento global. A medicina\nainda tem poucas respostas para\num em cada tr\u00eas pacientes com\nmeduloblastoma, cujos tumores\nretornam ap\u00f3s o tratamento.\nJuntos, n\u00f3s vamos mudar essa dura\nrealidade. Obrigado por nos ajudar a\nmelhorar a nossa compreens\u00e3o do\ntumor cerebral maligno mais comum\nem crian\u00e7as.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

UMA MISS\u00c3O URGENTE:
\nSalvar a vida de crian\u00e7as<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MEDULLOBLASTOMA<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O tumor cerebral mais comum<\/strong> em crian\u00e7as<\/p>

Sem tratamento estabelecido para recidiva<\/strong> \u2014\nque \u00e9 quase sempre fatal<\/p>

Muitas das crian\u00e7as que sobrevivem enfrentam\nsequelas f\u00edsicas e cognitivas por toda a vida<\/strong><\/p>

9 anos \u00e9 a idade m\u00e9dia<\/strong>\nde diagn\u00f3stico<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Um \"novo manual\" para curas<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Em janeiro, o MIT News, site oficial de not\u00edcias do Massachusetts Institute\nof Technology (MIT), destacou a nossa abordagem como um \"novo\nmanual\" para romper com o m\u00e9todo padr\u00e3o de desenvolvimento\nde curas para doen\u00e7as infantis. A equipe global dos sonhos da MBI\n\u00e9 fundamental para esse novo manual, sendo composta por 14\nlaborat\u00f3rios trabalhando lado a lado: o Cons\u00f3rcio Cure Group 4.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

No artigo, o Dr. Packer descreve esse modelo inovador. \u201cCriamos um\ncons\u00f3rcio de institui\u00e7\u00f5es l\u00edderes ao redor do mundo que realizam pesquisas\nsobre meduloblastoma, pedimos que mudassem\nsua abordagem laboratorial para se concentrar no\ntumor do Grupo 4 e atribu\u00edmos, a cada laborat\u00f3rio,\numa pergunta a ser respondida\u201d<\/strong>, diz ele. \u201cN\u00f3s os\nencarregamos de desenvolver terapias n\u00e3o em 7 a 10 anos,\nque \u00e9 a transi\u00e7\u00e3o normal entre a descoberta e o desenvolvimento de um\nmedicamento e sua chegada ao paciente, mas em um prazo de 2 anos.\u201d<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201cEssa meta altamente ambiciosa levou a resultados extraordin\u00e1rios\u201d<\/strong>, acrescenta o \n Dr. Packer. \u201cN\u00f3s nos\nbeneficiaremos de todo o impacto da MBI por gera\u00e7\u00f5es.\u201d<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Consortium Scientists<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Roger J. Packer, MD Children\u2019s National Hospital<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Eugene Hwang, MD Children\u2019s National Hospital<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Robert Wechsler-Reya, PhD Columbia<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Duane Mitchell, MD, PhD University of Florida<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Elias Sayour, MD, PhD University of Florida<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Michael Taylor, MD, PhD, Texas Children\u2019s Hospital<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Vijay Ramaswamy, MD, PhD SickKids<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Craig Daniels, PhD SickKids<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Yanxin Pei, PhD Children\u2019s National Hospital<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sheila Singh, MD, PhD McMaster University<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Tobey MacDonald, MD Emory University School of Medicine<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Lena M. Kutscher, PhD German Cancer Research Center<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Stefan Pfister, MD German Cancer Research Center<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t<\/i>\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t14 laborat\u00f3rios<\/strong>
\no nosso Cons\u00f3rcio do Grupo 4\n\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t<\/i>\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t18 l\u00edderes cient\u00edficos\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t<\/i>\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t 3 dos 5 especialistas mais citados*<\/strong>
\nem pesquisa sobre meduloblastoma<\/strong> em pesquisa sobre meduloblastoma\n\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\texpertscape.com<\/a>\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Consortium Scientists<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Dalia Haydar, PharmD, PhD Children\u2019s National Hospital<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Javad Nazarian, PhD Children\u2019s National Hospital<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Carl Koschmann, MD University of Michigan<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

William A. Weiss, MD, PhD University of California San Francisco<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Pesquisa com organoides: o elo perdido para a cura de tumores dif\u00edceis de tratar?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Parte do impacto duradouro da MBI em crian\u00e7as ao redor do mundo vir\u00e1 de novas descobertas\nsobre a impress\u00e3o digital molecular do meduloblastoma. Embora os ensaios cl\u00ednicos possam gerar\nnovas terapias hoje, os avan\u00e7os provenientes de estudos pr\u00e9-cl\u00ednicos t\u00eam o mesmo potencial para\ntransformar a \u00e1rea. Ainda que novos medicamentos geralmente sejam testados em modelos\nanimais, quatro pesquisadores da MBI adotaram uma abordagem diferente: organoides.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Os organoides s\u00e3o estruturas celulares tridimensionais cultivadas em laborat\u00f3rio. Os cientistas\nos geram a partir de c\u00e9lulas-tronco ou amostras de tecido de pacientes. Os organoides podem\nse desenvolver em estruturas multicelulares complexas que se assemelham a tecidos ou a\n\u00f3rg\u00e3os espec\u00edficos. Isso representa um grande potencial para a pesquisa de tumores cerebrais,\nparticularmente no caso do meduloblastoma do Grupo 4.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201cE se a origem celular do Grupo 4 n\u00e3o existir em camundongos?\u201d<\/strong>, perguntou o Dr. Robert WechslerReya, PhD, pesquisador da MBI da Universidade de Columbia, em uma reuni\u00e3o do Cons\u00f3rcio no\nin\u00edcio deste ano. Essa \u00e9 uma possibilidade real, pois a c\u00e9lula de origem da doen\u00e7a \u2013 a unipolar\nbrush cell (UBC) \u2013 \u00e9 extremamente rara em camundongos. Ao contr\u00e1rio das c\u00e9lulas UBC humanas,\nas de camundongos n\u00e3o se dividem. Isso significa que \u00e9 improv\u00e1vel que elas originem tumores. A\nincapacidade de se criar modelos murinos para o Grupo 4 dificultou a identifica\u00e7\u00e3o e o teste de\nnovas terapias para a doen\u00e7a. Os pesquisadores da MBI acreditam que pode ser mais f\u00e1cil criar\nmodelos usando organoides.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O membro do Cons\u00f3rcio Dr. Michael Taylor, MD, PhD, FRCS, do Hospital Texas Children\u2019s, lan\u00e7ou as\nbases para essa hip\u00f3tese ao ajudar a descobrir a c\u00e9lula de origem, tendo publicado o avan\u00e7o na\nprestigiada revista Nature. Quatro pesquisadores do Cons\u00f3rcio est\u00e3o desenvolvendo organoides\npara testar seu potencial:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2022 Dr. Wechsler-Reya na Columbia
Lena M. Kutscher, PhD, no
\u2022 German Cancer Research Center<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2022 Yanxin Pei, PhD, no Children\u2019s National Hospital
William A. Weiss, MD, PhD, na Universidade
da Calif\u00f3rnia, S\u00e3o Francisco<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A Dra. Pei obteve progressos significativos no desenvolvimento de um organoide espec\u00edfico para\nmeduloblastoma. Nos \u00faltimos meses, seu laborat\u00f3rio desenvolveu tecido organoide cerebelar,\nconfirmou a presen\u00e7a de UBC e encontrou dois oncogenes (genes com potencial para causar\nc\u00e2ncer) que podem fazer as c\u00e9lulas organoides crescerem. Atualmente, seu laborat\u00f3rio est\u00e1\ntestando o organoide para verificar se as c\u00e9lulas se assemelham ao meduloblastoma do Grupo 4.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A Dra. Kutscher est\u00e1 adotando uma abordagem diferente, em conson\u00e2ncia com a abordagem\neficiente da MBI, que evita pesquisas duplicadas. \u201cN\u00e3o existem modelos animais para muitos dos\ntumores que observamos em pacientes\u201d<\/strong>, afirma. \u201cEsperamos que os organoides preencham essa\nlacuna.\u201d<\/strong> A Dra. Kutscher rotula os progenitores da UBC e os concentra em um organoide. Isso cria\na possibilidade de um modelo de teste de medicamentos altamente espec\u00edfico para o Grupo 4, o\nque pode fornecer o elo que faltava para avan\u00e7os terap\u00eauticos e um progresso mais r\u00e1pido para\ncrian\u00e7as com tumores.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201cO investimento da MBI em ci\u00eancia b\u00e1sica, juntamente com as pesquisas pr\u00e9-cl\u00ednicas e cl\u00ednicas, far\u00e1\na diferen\u00e7a\"<\/strong>, afirma a Dra. Kutscher. \u201cEstamos todos trabalhando em dire\u00e7\u00e3o ao mesmo objetivo:\ndesenvolver curas.\u201d<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Reflex\u00f5es da jornada de Frederico<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201c<\/strong><\/em> O meduloblastoma do meu filho Frederico foi a fa\u00edsca que deu in\u00edcio \u00e0 MBI. Ele continua a inspirar meus esfor\u00e7os para ajudar crian\u00e7as ao redor do mundo. Com sua permiss\u00e3o, compartilhamos esta cole\u00e7\u00e3o de suas fotografias. Para mim, as fotos de Frederico oferecem janelas para a sua jornada.<\/span><\/em><\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2014 Fernando Goldztein<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Um ativo fundamental para ensaios cl\u00ednicos: a bi\u00f3psia l\u00edquida<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O laborat\u00f3rio da MBI no Hospital Children's National, liderado pelo Dr. Javad Nazarian, PhD,\ncontinua a aprimorar uma plataforma de bi\u00f3psia l\u00edquida. O Dr. Nazarian est\u00e1 na vanguarda\ndessa tecnologia emergente, que permite aos m\u00e9dicos detectar e rastrear o desenvolvimento de\ntumores com uma simples amostra de fluido corporal. Para pacientes do Grupo 4, ele planeja usar\no l\u00edquido cefalorraquidiano (LCR), um l\u00edquido transparente, semelhante ao plasma, que envolve\no c\u00e9rebro e a medula espinhal. Evid\u00eancias sugerem que o LCR pode fornecer informa\u00e7\u00f5es mais\nprecisas do que amostras de tecido tradicionais. Para o paciente, a coleta de uma amostra de\nLCR envolve menos desconforto, menos tempo e menor custo do que uma bi\u00f3psia de tecido\nconvencional.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A bi\u00f3psia l\u00edquida tamb\u00e9m promete impulsionar a pesquisa, \u00e0 medida que a MBI come\u00e7a a testar\nnovas terapias. \u201cQueremos responder aos sucessos e fracassos iniciais \u00e0 medida que avan\u00e7amos para\nos ensaios cl\u00ednicos\u201d<\/strong>, diz o Dr. Packer.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\"Nosso objetivo tem sido levar as plataformas de pesquisa para o ambiente cl\u00ednico\"<\/strong>, diz o Dr. Nazarian.\nSua equipe busca a certifica\u00e7\u00e3o do Clinical Laboratory Improvement Amendments (CLIA) para\na plataforma de bi\u00f3psia l\u00edquida do Grupo 4. Essa designa\u00e7\u00e3o garante a qualidade e a precis\u00e3o\ndos testes laboratoriais em humanos. \u201cA certifica\u00e7\u00e3o desses testes ser\u00e1 um grande passo \u00e0 frente na\ntransi\u00e7\u00e3o da nossa pesquisa para o tratamento cl\u00ednico.\u201d<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Outras atualiza\u00e7\u00f5es cient\u00edficas<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Cientistas dos 14 laborat\u00f3rios do Cons\u00f3rcio Cure Group 4 se reuniram no in\u00edcio de 2025 para\ndiscutir seus progressos mais recentes. Os principais destaques foram:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2022 A Dra. Dalia Haydar, PharmD, pesquisadora do Children\u2019s National especializada em\nimunoterapias com c\u00e9lulas T com receptor quim\u00e9rico de ant\u00edgeno (c\u00e9lulas CAR T), relatou\nresultados pr\u00e9-cl\u00ednicos promissores sobre a combina\u00e7\u00e3o do tratamento com c\u00e9lulas CAR T\ncom ondas de ultrassom para aumentar a penetra\u00e7\u00e3o tumoral. \"Essa combina\u00e7\u00e3o nos permite\nadministrar c\u00e9lulas CAR T de forma segura e eficiente sistemicamente \u2013 algo que n\u00e3o \u00e9 poss\u00edvel sem\nultrassom focalizado\"<\/strong>, explicou a Dra. Haydar. Ela tamb\u00e9m descreveu trabalhos futuros com o Dr.\nBrian Rood, MD, tamb\u00e9m do Children's National, para refinar os alvos dessa abordagem.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O Dr. Vijay Ramaswamy, MD, PhD, FRCPC, do SickKids Toronto, segue progredindo nos testes\ncom o Rapalink, um medicamento que tem como alvo a via de sinaliza\u00e7\u00e3o que os tumores do\nGrupo 4 usam para crescer. Estudos iniciais indicam que o medicamento pode funcionar bem\ncom outras terapias. Seu laborat\u00f3rio est\u00e1 realizando testes pr\u00e9-cl\u00ednicos para desenvolver um\nensaio cl\u00ednico para terapia combinada.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Obrigado<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Toda a equipe da MBI agradece o seu apoio \u00e0 nossa miss\u00e3o ou o seu interesse em saber\nmais. Estamos \u00e0 beira de avan\u00e7os importantes, uma conquista que se tornou poss\u00edvel\ngra\u00e7as \u00e0 a\u00e7\u00e3o coletiva da nossa comunidade. Seu apoio far\u00e1 a diferen\u00e7a para pacientes\nem todo o mundo. Juntos, salvaremos e melhoraremos vidas.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Depoimentos<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

“<\/strong>Os tumores do Grupo 4 s\u00e3o a forma mais comum de meduloblastoma. \u00c9 muito\nimportante investig\u00e1-los, visto que n\u00e3o os compreendemos t\u00e3o bem quanto\nos outros tipos. Isso requer uma investiga\u00e7\u00e3o aprofundada. O Cons\u00f3rcio Cure\nGroup 4 \u00e9 uma \u00f3tima equipe e est\u00e1 fazendo progressos reais. Estes s\u00e3o os\nespecialistas para fazer isso. O estudo do Dr. Mitchell \u00e9 incr\u00edvel. Ele far\u00e1 as\ncoisas acontecerem.<\/span><\/em><\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2014 Scott Pomeroy, MD, PhD<\/strong>
Membro do Conselho Consultivo do Cons\u00f3rcio Cure Group 4;\n Neurologista-chefe em\u00e9rito; Presidente em\u00e9rito,\n Departamento de Neurologia; Professor de Neurologia\n Bronson Crothers, Escola de Medicina de Harvard<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

“<\/strong>A MBI representa um esfor\u00e7o cr\u00edtico e focado para enfrentar um c\u00e2ncer\ninfantil devastador. Seu compromisso em acelerar o ritmo das descobertas\ne levar terapias inovadoras a crian\u00e7as com meduloblastoma, promovendo a\ncolabora\u00e7\u00e3o entre pesquisadores, m\u00e9dicos e defensores de pacientes, alinhase perfeitamente com a miss\u00e3o da American Society of Clinical Oncology\n(ASCO) de combater o c\u00e2ncer por meio de pesquisa, educa\u00e7\u00e3o e promo\u00e7\u00e3o\nda mais alta qualidade no atendimento ao paciente. A ASCO e nossa\nFunda\u00e7\u00e3o Conquer Cancer apoiam integralmente o trabalho vital da MBI e seu\npotencial para causar um impacto significativo na vida de crian\u00e7as e fam\u00edlias\nque enfrentam esse diagn\u00f3stico desafiador.<\/span><\/em><\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2014 Clifford Hudis, MD, FACP, FASCO<\/strong>
Diretor Executivo, American Society of Clinical Oncology<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

“<\/strong>A MBI \u00e9 exatamente o tipo de cons\u00f3rcio de pesquisa altamente focado, rico\nem talentos e com recursos inteligentes, que \u00e9 necess\u00e1rio para acelerar\nrapidamente o ritmo de desenvolvimento de tratamentos para um dos\nc\u00e2nceres cerebrais mais dif\u00edceis que afetam crian\u00e7as, o meduloblastoma do\nGrupo 4. A equipe de lideran\u00e7a da MBI est\u00e1 reunindo a comunidade afetada\npor tumores cerebrais para construir uma onda de interesse e apoio que\nalimente esperan\u00e7a e d\u00ea \u00e0 pesquisa a melhor chance de transformar o que\nantes era intrat\u00e1vel em algo potencialmente cur\u00e1vel.<\/span><\/em><\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2014\u00a0David Arons, JD<\/strong>
Presidente e CEO, National Brain Tumor Society<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

“<\/strong>Recentemente conheci a MBI, um projeto liderado por brasileiros que\nrealmente me chamou a aten\u00e7\u00e3o por sua abordagem inovadora. O\nprojeto agora re\u00fane 14 institui\u00e7\u00f5es dos Estados Unidos e de outras partes\ndo mundo, com uma estrutura ousada e eficiente. Conseguiu mobilizar\nalguns dos principais cientistas do mundo e j\u00e1 est\u00e1 alcan\u00e7ando resultados\nimpressionantes. Aderi \u00e0 iniciativa porque acredito em seu potencial\ntransformador. Ela tem tudo o que \u00e9 preciso para fazer uma diferen\u00e7a real no\nfuturo de muitas crian\u00e7as.<\/span><\/em><\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2014 Luis Stuhlberger<\/strong>
CEO da Verde Asset Management, apoiadora filantr\u00f3pica da MBI<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\n\t\n<\/svg>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Relat\u00f3rio N\u00ba 8<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

The
\nMedulloblastoma
\nInitiative<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Fernando Goldsztein: Fundador<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mauro Dorfman: Coordenador estrat\u00e9gico<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Martina Fischer: Gest\u00e3o de projeto<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Claudia Buchweitz\/Scientific Linguagem:\nCoordenadora estrat\u00e9gica<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Iago Paz\/Scientific Linguagem: Design e\ndesenvolvimento<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Lu\u00edsa de Abreu\/Scientific Linguagem: Translation and revision<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Caroline Postay\/Scientific Linguagem: Translation and revision<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Francesca Tantazzi: Consultora<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Jyothi Raghavan: Representante l\u00edder de\ncomunidade<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Katherine Fontan: Desk research<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Fbiz: Publicidade e m\u00eddias sociais<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Digital Trix: Assessoria de imprensa e RP no Brasil<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sunshine Sachs Morgan & Lylis: Assessoria de\nimprensa e RP
nos Estados Unidos<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

” <\/strong><\/em><\/span><\/span>Quem salva uma vida salva o mundo inteiro<\/em><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

- Talmud<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Children\u2019s National Hospital Foundation<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mandy Ranalli: Vice-Presidente Associada, Grandes Doa\u00e7\u00f5es Internacionais<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Andrew Miller: Diretor de Desenvolvimento, Neuroci\u00eancias e Medicina Comportamental<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Erin Whiteman: Diretora Associada, Grandes Doa\u00e7\u00f5es<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Paige Mulry: Coordenadora de Desenvolvimento, Grandes Doa\u00e7\u00f5es e Avan\u00e7o Internacional<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Emma Younger: Assistente de Desenvolvimento<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Conselho Consultivo Cient\u00edfico<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sidnei Epelman, MD, Hospital Santa Marcelina,\nS\u00e3o Paulo, Brasil<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Stewart Goldman, MD, Phoenix Children's\nHospital, University of Arizona<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Scott Pomeroy, MD, PhD, Boston Children\u2019s\nHospital, Harvard Medical School<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Rajeev Vibhakar, MD, PhD, MPH\/MSPH, Children\u2019s\nHospital Colorado, University of Colorado<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Consellho Consultivo da MBI<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Paula Puppi<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Claudio Galv\u00e3o de Castro<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Ricardo Sales<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Claudia Buchweitz<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mauro Dorfman<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Fernando Goldsztein<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Fernando Goldsztein foi entrevistado na Fox 5 News, em Washington, D.C., durante o M\u00eas de Conscientiza\u00e7\u00e3o sobre Tumores\nCerebrais, em maio, para destacar os esfor\u00e7os do MBI na busca por novas curas.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\n\t\n<\/svg>\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00c9 poss\u00edvel dar ESPERAN\u00c7A<\/strong> a crian\u00e7as
\ncom tumores cerebrais letais?
A MBI diz SIM<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Apoie a MBI hoje<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

The Medulloblastoma Initiative Impact Report May 2025 Duane Mitchell, MD, PhD, leads the MBI\u2019s first FDA-approved clinical trial at the University of Florida. Making History: Our First Clinical Trial Begins The Medulloblastoma Initiative (MBI) is helping transform the field of brain tumor research. This spring, investigators at the University of Florida launched the MBI\u2019s first […]<\/p>","protected":false},"author":11,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4842","page","type-page","status-publish","hentry"],"yoast_head":"\nImpact Report - The Medulloblastoma Initiative<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mbinitiative.org\/pt\/impact-report\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Impact Report - The Medulloblastoma Initiative\" \/>\n<meta property=\"og:description\" content=\"The Medulloblastoma Initiative Impact Report May 2025 Duane Mitchell, MD, PhD, leads the MBI\u2019s first FDA-approved clinical trial at the University of Florida. Making History: Our First Clinical Trial Begins The Medulloblastoma Initiative (MBI) is helping transform the field of brain tumor research. This spring, investigators at the University of Florida launched the MBI\u2019s first […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mbinitiative.org\/pt\/impact-report\/\" \/>\n<meta property=\"og:site_name\" content=\"The Medulloblastoma Initiative\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/themedulloblastomainitiative\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-25T17:54:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/11\/logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"591\" \/>\n\t<meta property=\"og:image:height\" content=\"262\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"16 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mbinitiative.org\/impact-report\/\",\"url\":\"https:\/\/mbinitiative.org\/impact-report\/\",\"name\":\"Impact Report - The Medulloblastoma Initiative\",\"isPartOf\":{\"@id\":\"https:\/\/mbinitiative.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mbinitiative.org\/impact-report\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mbinitiative.org\/impact-report\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2025\/02\/image-26-1.svg\",\"datePublished\":\"2025-05-28T05:17:40+00:00\",\"dateModified\":\"2025-06-25T17:54:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/mbinitiative.org\/impact-report\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mbinitiative.org\/impact-report\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/mbinitiative.org\/impact-report\/#primaryimage\",\"url\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2025\/02\/image-26-1.svg\",\"contentUrl\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2025\/02\/image-26-1.svg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mbinitiative.org\/impact-report\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/mbinitiative.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Impact Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mbinitiative.org\/#website\",\"url\":\"https:\/\/mbinitiative.org\/\",\"name\":\"The Medulloblastoma Initiative\",\"description\":\"Cura do Meduloblastoma Infantil\",\"publisher\":{\"@id\":\"https:\/\/mbinitiative.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mbinitiative.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mbinitiative.org\/#organization\",\"name\":\"The Medulloblastoma Initiative\",\"url\":\"https:\/\/mbinitiative.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/mbinitiative.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/10\/LOGO-MBI.png\",\"contentUrl\":\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/10\/LOGO-MBI.png\",\"width\":354,\"height\":168,\"caption\":\"The Medulloblastoma Initiative\"},\"image\":{\"@id\":\"https:\/\/mbinitiative.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/themedulloblastomainitiative\",\"https:\/\/www.instagram.com\/medulloblastomainitiative\/\",\"https:\/\/www.linkedin.com\/company\/medulloblastomainitiative\/\",\"https:\/\/www.youtube.com\/@mbinitiative\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Impact Report - The Medulloblastoma Initiative","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mbinitiative.org\/pt\/impact-report\/","og_locale":"pt_BR","og_type":"article","og_title":"Impact Report - The Medulloblastoma Initiative","og_description":"The Medulloblastoma Initiative Impact Report May 2025 Duane Mitchell, MD, PhD, leads the MBI\u2019s first FDA-approved clinical trial at the University of Florida. Making History: Our First Clinical Trial Begins The Medulloblastoma Initiative (MBI) is helping transform the field of brain tumor research. This spring, investigators at the University of Florida launched the MBI\u2019s first […]","og_url":"https:\/\/mbinitiative.org\/pt\/impact-report\/","og_site_name":"The Medulloblastoma Initiative","article_publisher":"https:\/\/www.facebook.com\/themedulloblastomainitiative","article_modified_time":"2025-06-25T17:54:05+00:00","og_image":[{"width":591,"height":262,"url":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/11\/logo.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. tempo de leitura":"16 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/mbinitiative.org\/impact-report\/","url":"https:\/\/mbinitiative.org\/impact-report\/","name":"Impact Report - The Medulloblastoma Initiative","isPartOf":{"@id":"https:\/\/mbinitiative.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mbinitiative.org\/impact-report\/#primaryimage"},"image":{"@id":"https:\/\/mbinitiative.org\/impact-report\/#primaryimage"},"thumbnailUrl":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2025\/02\/image-26-1.svg","datePublished":"2025-05-28T05:17:40+00:00","dateModified":"2025-06-25T17:54:05+00:00","breadcrumb":{"@id":"https:\/\/mbinitiative.org\/impact-report\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mbinitiative.org\/impact-report\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/mbinitiative.org\/impact-report\/#primaryimage","url":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2025\/02\/image-26-1.svg","contentUrl":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2025\/02\/image-26-1.svg"},{"@type":"BreadcrumbList","@id":"https:\/\/mbinitiative.org\/impact-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/mbinitiative.org\/"},{"@type":"ListItem","position":2,"name":"Impact Report"}]},{"@type":"WebSite","@id":"https:\/\/mbinitiative.org\/#website","url":"https:\/\/mbinitiative.org\/","name":"(The Medulloblastoma Initiative)","description":"Cura do Meduloblastoma Infantil","publisher":{"@id":"https:\/\/mbinitiative.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mbinitiative.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/mbinitiative.org\/#organization","name":"(The Medulloblastoma Initiative)","url":"https:\/\/mbinitiative.org\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/mbinitiative.org\/#\/schema\/logo\/image\/","url":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/10\/LOGO-MBI.png","contentUrl":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/10\/LOGO-MBI.png","width":354,"height":168,"caption":"The Medulloblastoma Initiative"},"image":{"@id":"https:\/\/mbinitiative.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/themedulloblastomainitiative","https:\/\/www.instagram.com\/medulloblastomainitiative\/","https:\/\/www.linkedin.com\/company\/medulloblastomainitiative\/","https:\/\/www.youtube.com\/@mbinitiative"]}]}},"_links":{"self":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/pages\/4842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/comments?post=4842"}],"version-history":[{"count":238,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/pages\/4842\/revisions"}],"predecessor-version":[{"id":5351,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/pages\/4842\/revisions\/5351"}],"wp:attachment":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/media?parent=4842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}